Clinical Trial: Safety and Efficacy of KSVCBD Injection in B-cell Non-Hodgkin's Lymphoma Expressing CD19 and/or BCMA

U.S., June 3 -- ClinicalTrials.gov registry received information related to the study (NCT07620314) titled 'Safety and Efficacy of KSVCBD Injection in B-cell Non-Hodgkin's Lymphoma Expressing CD19 and/or BCMA' on May 27.

Brief Summary: KSVCBD injection is an in vivo Chimeric Antigen Receptor T-Cell (CAR-T cell) therapy product. This multicenter, single-arm, open-label, early exploratory clinical study is designed to evaluate the preliminary safety and efficacy of KSVCBD injection in patients with relapsed or refractory (r/r) B-cell non-Hodgkin's lymphoma (NHL) CD19 and/or BCMA.

Study Start Date: June 15

Study Type: INTERVENTIONAL

Condition: Non-Hodgkin's Lymphoma

Intervention: BIOLOGICAL: KSVCBD injection

KSVCBD injection is an in v...